UBE3C

Mutation & survival
SurvivalMutationKaplan–Meier · TCGA cohorts

Across TCGA pan-cancer cohorts, UBE3C Mutation is linked to patient survival in 5 of 34 cancer types, making it a survival-associated UBE3C data layer compared with 22 for mass-spec protein and 5 for mass-spec protein.

The strongest signal is observed in kidney chromophobe (KICH), where higher UBE3C Mutation is associated with worse disease-free survival. In most high-consensus cancer types, elevated UBE3C expression acts as an unfavorable survival marker, although some lineages such as UCEC and SKCM show a favorable association.

KICH, UCEC, and SARC are the cancer types where UBE3C Mutation most reproducibly stratifies survival.

Mutation survival associations by lineage

Ranked by sampling consensus. AUC1 and AUC2 indicate survival in the high- and low-expression groups, respectively; the lower AUC marks the poorer-surviving group. p-values are from the log-rank test.
LineageMeasureSplitStageAUC1
high
AUC2
low
pSampling consensus
KICHDFSMedianAll0.0810.904<.00130view →
UCECDFSMedianAll0.7650.630.00820view →
SARCDFSMedianAll0.0060.591<.0013view →
LUADDFSMedianII,III,IV0.2580.683.0483view →
SKCMOSMedianAll1.0000.867.0373view →
Pink = unfavorable, green = favorable. Showing the 5 strongest of 5 lineages.

UBE3C–KICH (DFS)

Kaplan–Meier survival curve for UBE3C mutant vs wild-type samples in KICH.

Open the KICH breakdown →

Exploration